EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CAPN6 Is Upregulated in Trastuzumab-Resistant HER2-Positive Breast Cancer Cells and Modulates Rac1/PAK1-Related Signaling and T-DM1 Response

Chenguang Zhang, Yulou Luo, Yilina Saibaidula, Jianghua Ou

Cancer Treatment and Research Communications · 2026-11 · 101536

DOI: 10.1016/j.ctarc.2026.101536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026-11. Verfasst von Chenguang Zhang und 3 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to trastuzumab limits the clinical benefit of HER2-targeted therapy in HER2-positive breast cancer. CAPN6 has been reported to participate in tumor progression and treatment resistance, but its role in trastuzumab resistance remains unclear. Here, we explored the expression of CAPN6 and its potential association with resistant-cell behavior in HER2-positive breast cancer cells. CAPN6 mRNA and protein expression were significantly increased in trastuzumab-resistant SKBR-3R cells compared with parental SKBR-3 cells. CCK-8 assays showed that CAPN6 overexpression was associated with enhanced cell viability, whereas CAPN6 knockdown reduced cell viability. Western blot analysis further showed elevated Rac1 and PAK1 protein levels in resistant cells. Moreover, Rac1 silencing attenuated the increased viability observed in CAPN6-overexpressing cells, suggesting that Rac1/PAK1-related signaling may be involved in CAPN6-associated phenotypic changes. In T-DM1-treated resistant cells, CAPN6 modulation was accompanied by corresponding changes in cell viability and Rac1/PAK1 protein expression. Taken together, these results suggest that CAPN6 is upregulated in trastuzumab-resistant HER2-positive breast cancer cells and may contribute to the resistant phenotype, potentially in association with Rac1/PAK1-related signaling. Further studies are required to clarify the precise molecular mechanism and therapeutic relevance of CAPN6 in trastuzumab resistance.

Zitieren

APA

Zhang, C., Luo, Y., Saibaidula, Y., & Ou, J. (2026). CAPN6 Is Upregulated in Trastuzumab-Resistant HER2-Positive Breast Cancer Cells and Modulates Rac1/PAK1-Related Signaling and T-DM1 Response. Cancer Treatment and Research Communications, 101536. https://doi.org/10.1016/j.ctarc.2026.101536

Vancouver

Zhang C, Luo Y, Saibaidula Y, Ou J. CAPN6 Is Upregulated in Trastuzumab-Resistant HER2-Positive Breast Cancer Cells and Modulates Rac1/PAK1-Related Signaling and T-DM1 Response. Cancer Treatment and Research Communications. 2026:101536. doi:10.1016/j.ctarc.2026.101536

BibTeX
@article{Zhang2026,
  author = {Zhang, Chenguang and Luo, Yulou and Saibaidula, Yilina and Ou, Jianghua},
  title = {CAPN6 Is Upregulated in Trastuzumab-Resistant HER2-Positive Breast Cancer Cells and Modulates Rac1/PAK1-Related Signaling and T-DM1 Response},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  pages = {101536},
  doi = {10.1016/j.ctarc.2026.101536}
}
Kostenlos starten →